Mota, PedroPires, Rita F.Serpa, JacintaSerpa, JacintaBonifácio, Vasco D.B.2019-09-102019-09-102019-08-27PURE: 14632436PURE UUID: 85a0c750-ef22-4378-898b-fc00f9d95262Scopus: 85071401447PubMed: 31461931ORCID: /0000-0002-1548-5907/work/63053981WOS: 000488613700091http://www.scopus.com/inward/record.url?scp=85071401447&partnerID=8YFLogxKl-Buthionine sulfoximine (l-BSO) is an adjuvant drug that is reported to increase the sensitivity of cancer cells to neoplastic agents. Dendrimers are exceptional drug delivery systems and l-BSO nanoformulations are envisaged as potential chemotherapeutics. The absorption of l-BSO at a low wavelength limits its detection by conventional analytical tools. A simple and sensitive method for l-BSO detection and quantification is now reported. In this study, l-BSO was encapsulated in a folate-targeted generation four polyurea dendrimer (PUREG4-FA2) and its release profile was followed for 24 h at pH 7.4 and 37 ◦C. The protocol uses in situ l-BSO derivatization, by the formation of a catechol-derived orto-quinone, followed by visible detection of the derivative at 503 nm. The structure of the studied l-BSO derivative was assessed by NMR spectroscopy.1982982engButhionine sulfoximineCatecholDerivatizationNanoformulationPolyurea dendrimersUV-Vis detectionAnalytical ChemistryChemistry (miscellaneous)Molecular MedicinePharmaceutical ScienceDrug DiscoveryPhysical and Theoretical ChemistryOrganic ChemistrySDG 3 - Good Health and Well-beingjournal article10.3390/molecules24173111https://www.scopus.com/pages/publications/85071401447